-
Guangzhou Wondfo Biotech Partners with Indonesia’s Kimia Farma in IVD Field
•
China-based Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482) has entered into a partnership with Indonesia’s state-owned pharmaceutical company, Kimia Farma (KAEF), in the in vitro diagnostics (IVD) field. The collaboration aims to strengthen the healthcare infrastructure in Indonesia, although no financial details have been disclosed. Background on Kimia Farma and…
-
InxMed Partners with GeneQuantum Healthcare to Develop Innovative ADCs
•
China-based firm InxMed (Nanjing) Co., Ltd has announced a strategic partnership with compatriot firm GeneQuantum Healthcare. Under the terms of the agreement, GeneQuantum will grant InxMed a non-exclusive license to utilize its independently developed and globally leading core coupling technologies for the development of innovative antibody drug conjugates (ADCs). Access…
-
Sansure Biotech Partners with Indonesian Firm for Localized Molecular Diagnostic Production
•
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced a strategic partnership with an undisclosed firm from Indonesia. The collaboration will focus on the localized production of molecular diagnostic reagents and equipment, as well as other in vitro diagnostic (IVD) products. The partnership aims to train local molecular…
-
Sinopharm Partners with Harbin Institute of Technology to Boost Biomedical Industry Innovation
•
China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strategic partnership with Harbin Institute of Technology, aimed at strengthening scientific and technological exchanges. The collaboration focuses on high-level national priorities, including accelerating self-reliance and self-improvement in high-level science and technology, serving the country’s rejuvenation through science and education,…
-
NK Celltech and RongCan Biotech Partner to Advance mRNA NK Cell Therapy and LNP Delivery System
•
Shanghai-based NK Celltech and RongCan Biotech have entered into a partnership agreement to establish a long-term collaboration in the field of LNP delivery systems, aiming to bolster the clinical application of mRNA on NK cell therapy. The financial details of the agreement have not been disclosed. Complementary Expertise and PlatformsNK…
-
Abbisko Therapeutics Initiates Phase II Clinical Trial for Pimicotinib in Tendon Sheath Giant Cell Tumor
•
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the dosing of the first patient in a Phase II clinical study for its Category 1 drug ABSK021 (pimicotinib) in tendon sheath giant cell tumor (TGCT) in the United States. Phase III Study Design and ObjectivesThe upcoming randomized, double-blind, placebo-controlled…
-
CASI Pharmaceuticals Enters Assignment Agreement with Mundipharma for Folotyn Commercialization in China
•
US-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has announced the execution of an assignment agreement with Mundipharma International Corporation Limited (MICL), Mundipharma Medical Company (MMCo), and Acrotech Biopharma Inc. (Acrotech) for the commercialization of Folotyn (pralatrexate) in China. The financial details of the agreement have not been disclosed. Folotyn (Pralatrexate) for…
-
Astellas Pharma’s Zolbetuximab BLA Accepted by China’s CDE for Gastric Cancer Treatment
•
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the Center for Drug Evaluation (CDE) in China has accepted the Biologics License Application (BLA) for zolbetuximab, a first-in-class investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody (mAb), for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or…
